Volume 1.34 | Dec 14

Pancreatic Cell News 1.34, December 14, 2010.


Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer  ShareThis
Scientists report the remarkable clinical outcome of a patient with advanced, gemcitabine-resistant, pancreatic cancer who was later treated with DNA damaging agents, based on the observation of significant activity of this class of drugs against a personalized xenograft generated from the patient’s surgically resected tumor. [Mol Cancer Ther]

Request a Sample  
Fast Isolation of Highly Purified Mouse B Cells
with EasySep®


Interested in recruiting talented individuals? Post your career opportunities in Pancreatic Cell News at no cost. Contact us at [email protected]

Twitter Follow us on Twitter! @PancreaticCell


“Grow Your Own Transplant” May be Possible for Men with Type 1 Diabetes
Men with type 1 diabetes may be able to grow their own insulin-producing cells from their testicular tissue, say researchers. [Press release from Georgetown University Medical Center discussing research presented at the 50th American Society of Cell Biology Meeting]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


A Strategy for the Engineering of Insulin Producing Cells with a Broad Spectrum of Defense Properties
Researchers present a novel in vivo selection strategy based on the isolation of insulin-producing cells with enhanced protection after repeated rounds of encapsulation and xenotransplantation. [Biomaterials]

Altered Dipeptidyl Peptidase 4 Activity during the Progression of Hyperinsulinemic Obesity and Islet Atrophy in Spontaneously Late-Stage Type 2 Diabetic Rats
Altered dipeptidyl peptidase 4 activity during the progression of late-stage type 2 diabetes was measured in Otsuka Long-Evans Tokushima fatty rats. [Am J Physiol Endocrinol Metab]

Effect of Hypoxia-Inducible VEGF Gene Expression on Revascularization and Graft Function in Mouse Islet Transplantation
The aim of this study was to investigate the effects of hypoxia-inducible vascular endothelial growth factor (VEGF) gene transfer using the RTP801 promoter on islet grafts. [Transpl Int

Glucose-Induced Regulation of NHEs Activity and SGLTs Expression Involves the PKA Signaling Pathway
The effect of glucose on the intracellular pH recovery rate and Na(+)-glucose transporter (SGLT) localization was investigated in HEK-293 cells, a cell line that expresses endogenous NA+/H+ exchanger (NHE)1, NHE3, SGLT1, and SGLT2 proteins. [J Membr Biol]


The CD40-CD154 Interaction Would Correlate with Proliferation and Immune Escape in Pancreatic Ductal Adenocarcinoma
The results suggest that the CD40-CD154 interaction would correlate with cell proliferation and secretion of cytokines in pancreatic ductal adenocarcinoma (PDAC) cells, and CD154 overexpression could be a favorable prognostic factor in PDAC patients. [J Surg Oncol]

Overexpression of Fibroblast Growth Factor Receptor 4 in High-Grade Pancreatic Intraepithelial Neoplasia and Pancreatic Ductal Adenocarcinoma
Investigators showed that fibroblast growth factor receptor (FGFR) 4 expression is markedly increased in high-grade pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma (PDAC) compared with that in normal and low-grade PanIN, and that FGFR4 stimulation by FGF19 of PDAC cells contributes to tumor suppression by increasing cell adhesion to extracellular matrix. [Int J  Oncol]

SKP2 Confers Resistance of Pancreatic Cancer Cells Towards TRAIL-Induced Apoptosis
Using RNA interference researchers demonstrate that S-phase kinase associated protein 2 (SKP2) confers resistance of a subset of pancreatic ductal adenocarcinoma cell lines towards the tumor necrosis factor-related apoptosis-inducing ligand, but not the topoisomerase II inhibitor etoposide. [Int J  Oncol]

KNK437 Downregulates Heat Shock Protein 27 of Pancreatic Cancer Cells and Enhances the Cytotoxic Effect of Gemcitabine
This report describes the benefits of a treatment strategy combining the heat shock protein inhibitor KNK437 with gemcitabine (GEM) for GEM-resistant pancreatic cancer cells. [Chemotherapy]


MonoSol Rx and Midatech to Develop Insulin in PharmFilm®; To Establish Joint Venture
MonoSol Rx and Midatech Group Ltd. announced their intent to form a joint venture that will focus on the development and commercialization of products combining the two companies’ respective technologies in the diabetes field. [Midatech Group Ltd. Press Release]

Access Pharmaceuticals Signs Agreement with Major Global Pharmaceutical Company for Its CobOral™ Oral Insulin Formulation
Access Pharmaceuticals, Inc. announced it has entered into an agreement with a major global pharmaceutical company to test Access’ oral insulin formulation based upon its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology. [Access Pharmaceuticals, Inc. Press Release]

Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device
Valeritas, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s V-Go Disposable Insulin Delivery Device for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin. [Valeritas, Inc. Press Release]

Medtronic Launches CareLink Pro 3.0, the First Diabetes Management Software to Offer Advanced Decision Support
Medtronic, Inc. announced the Food and Drug Administration approval and the market launch of CareLink® Pro 3.0 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes. [Medtronic, Inc. Press Release]

Aduro BioTech’s Clinical Results from CRS-207 Phase I Trial Presented at AACR Special Conference
Aduro BioTech announced the presentation of the CRS-207 Phase I study at the AACR Special Conference on Tumor Immunology in Miami, Florida by the Principal Investigator, Dr. Dung Le of the Johns Hopkins Kimmel Cancer Center. [Business Wire]

Spherix Phase II Trial with D-Tagatose Determines Minimum Dose for HbA1c and Triglycerides
Spherix Incorporated announced that its Phase II diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested (2.5, 5.0, and 7.5 g TID), with the 2.5 and 5.0 g doses producing similar responses to one another, and the 7.5 g dose producing a greater response. [Spherix Incorporated Press Release]

LCT’s DIABECELL® Registered for Sale and Use in Russia
Living Cell Technologies Limited announced that its Russian subsidiary, LCT Biomedical Limited, has received registration of the Company’s groundbreaking diabetes treatment, DIABECELL, as a marketable medical technology in Russia. [Living Cell Technologies Limited Press Release]

EctoPharma Awarded Top SMART: SCOTLAND Grant
EctoPharma announces that the Company has been awarded the maximum Feasibility Study grant of £70,000 under Scottish Enterprise’s SMART: SCOTLAND Scheme which supports innovative research and development projects within small and medium sized enterprises in Scotland. [EctoPharma Press Release]

Albert Einstein College of Medicine to Study Impact of Resveratrol on Prediabetes
Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded $600,000 from the American Diabetes Association to study the effect of resveratrol, a chemical compound most notably found in red wine and grapes, on impaired glucose tolerance in older adults. [Albert Einstein College of Medicine of Yeshiva University Press Release]

JDRF Applauds Congress for Passage of $300 Million for Type 1 Diabetes Research and Thanks Supporters for Advocacy Efforts for Special Diabetes Program Renewal
Congress passed a multi-year renewal of the Special Diabetes Program, ensuring that studies on promising diabetes treatments and avenues toward a cure continue uninterrupted. [Juvenile Diabetes Research Foundation (JDRF) International Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)
Medicines and Healthcare Products Regulatory Agency (United Kingdom)

National Health Service (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS (Listed by Date)

Pharmacology in Stem Cells Research and Regenerative Medicine
December 17, 2010
London, United Kingdom

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction
January 12-17, 2011
Dillon, United States

Keystone Symposia: Obesity
January 12-17, 2011
Keystone, United States

2011 Gastrointestinal Cancers Symposium
January 20-22, 2011
San Francisco, United States

Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, D.C., United States

Early Development for Innovative Diabetes & Metabolic Syndrome Therapeutics Conference
January 26-27, 2011
Amsterdam, The Netherlands

Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club
February 10-13, 2011
Maradu, India

2nd Annual International Diabetes Summit
February 22-24, 2011
Dubai, United Arab Emirates

World Cell Culture Congress 2011
February 28-March 2, 2011
Munich, Germany

March 13-18, 2011
Atlanta, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

World Stem Cells & Regenerative Medicine Congress 2011
May 9-11, 2011
London, United Kingdom

13th Annual C21 BioVentures
May 24-26, 2011
Napa, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Lab Technologist – Cell Separation (STEMCELL Technologies)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

here to post your career opportunities.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Pancreatic Cell News: Archives | Events | Contact Us